Plain-English translation of NCT03183661 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Crohn Disease research guide →This is a follow-up study for people who already received , an injection of special healing cells from fat tissue, as part of an earlier clinical trial. Researchers want to make sure the medication continues to be safe over the next three years. The treatment works by reducing inflammation and calming the immune system, which may help people with Crohn's disease.
When a new treatment is tested, researchers need to follow patients long-term to watch for any delayed side effects or changes in health. This study continues that important safety monitoring for this medication.
You likely qualify if…
You likely don't qualify if…
You will continue to be monitored for safety over 36 months (three years). This involves regular check-ins where the research team will assess how you're doing and watch for any side effects or health changes related to the treatment you received. The study is open-label, meaning both you and your doctors will know you received the stem cell injection.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
South Korea
Anterogen Co., Ltd.
Enrollment target
~9 participants
Started
November 2016
Primary completion
December 2026
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in August 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jae Hee Cheon, Ph D
Yonsei University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.